PTC Fully Enrolls Duchenne MD Trial; Expects Top-Line Data In Early 2010
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Despite targeting an indication with a very small population, PTC Therapeutics has fully enrolled a pivotal trial for ataluren (PTC124), its potential disease-modifying therapy for Duchenne muscular dystrophy, and expects to produce top-line data early next year. Regulatory filings in the U.S. and EU could follow closely if the data are promising